Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Net Income towards Common Stockholders (2016 - 2023)

Historic Net Income towards Common Stockholders for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to $58.9 million.

  • RedHill Biopharma's Net Income towards Common Stockholders rose 79179.66% to $58.9 million in Q2 2023 from the same period last year, while for Dec 2024 it was $58.9 million, marking a year-over-year increase of 41816.51%. This contributed to the annual value of -$8.3 million for FY2024, which is 13457.1% down from last year.
  • Latest data reveals that RedHill Biopharma reported Net Income towards Common Stockholders of $58.9 million as of Q2 2023, which was up 79179.66% from -$7.9 million recorded in Q1 2023.
  • RedHill Biopharma's 5-year Net Income towards Common Stockholders high stood at $58.9 million for Q2 2023, and its period low was -$145.2 million during Q4 2021.
  • For the 5-year period, RedHill Biopharma's Net Income towards Common Stockholders averaged around -$1.3 million, with its median value being $11.1 million (2019).
  • Per our database at Business Quant, RedHill Biopharma's Net Income towards Common Stockholders crashed by 106284.39% in 2021 and then soared by 79179.66% in 2023.
  • Over the past 5 years, RedHill Biopharma's Net Income towards Common Stockholders (Quarter) stood at $11.8 million in 2019, then increased by 27.44% to $15.1 million in 2020, then crashed by 1062.84% to -$145.2 million in 2021, then soared by 52.14% to -$69.5 million in 2022, then soared by 184.75% to $58.9 million in 2023.
  • Its Net Income towards Common Stockholders stands at $58.9 million for Q2 2023, versus -$7.9 million for Q1 2023 and -$69.5 million for Q4 2022.